<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02214862</url>
  </required_header>
  <id_info>
    <org_study_id>PI11/02031</org_study_id>
    <nct_id>NCT02214862</nct_id>
  </id_info>
  <brief_title>2-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism</brief_title>
  <acronym>[F18]-FDDNP</acronym>
  <official_title>Pilot, Exploratory Study With [F18]-FDDNP-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion Clinic per a la Recerca Biomédica</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion Clinic per a la Recerca Biomédica</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PET tracer [F18]-FDDNP has a specific affinity for lesions containing tau protein.

      The study consists of two phases:

        -  In the first (cross-sectional) phase it will be assessed the uptake of [18F]-FDDNP in 10
           cases with progressive supranuclear palsy (PSP, a tauopathy) en 10 with multi-system
           atrophy (MSA, a non-tauopathy), along with 20 individuals with Unclassifiable
           Parkinsonism, as previously defined in a European cohort study.

        -  In the second (longitudinal) phase it will be prospectively followed the 20
           unclassifiable patients (at 6, 12 and 18 months) by means of validated scales and
           accepted diagnostic criteria in order to try to correlate their eventual clinical
           diagnosis with baseline PET findings. On this basis, we endeavour to estimate the
           ability of this technique to detect in vivo underlying tau pathology in subjects
           initially unclassifiable on clinical grounds.

      We hypothesized that:

        1. Patients with clinically definite PSP will present an increased uptake in basal ganglia,
           brainstem and cerebellum.

        2. Patients with clinically defined MSA will not present specific uptake.

        3. Part of unclassifiable patients with parkinsonism will present a pattern of uptake
           similar to patients with clinically defined PSP and this part along the clinical
           follow-up will be meet clinical criteria for diagnose of PSP
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the Relative Volume of Distribution of [18F]-FDDNP in individuals with unclassifiable parkinsonism, and to try to correlate their eventual clinical diagnosis with baseline PET findings.</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>to assess the uptake of [18F]-FDDNP in cases clinically defined of progressive supranuclear palsy and multi-system atrophy</measure>
    <time_frame>Baseline assessment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the ability to detect in vivo underlying tau pathology in unclassifiable parkinsonism by means of PET -[18F]-FDDNP.</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Progressive Supranuclear Palsy</condition>
  <condition>Multi-System Atrophy</condition>
  <condition>Parkinsonism</condition>
  <arm_group>
    <arm_group_label>[F18]-FDDNP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2-(1-{6-[(2-[F-18]fluoroethyl) (methyl)amino]-2-naphthyl} ethylidene) malononitrile Radiopharmaceutical tracer, intravenous, single dose of 360+/-20 megabecquerel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[F18]-FDDNP</intervention_name>
    <description>radiopharmaceutical tracer</description>
    <arm_group_label>[F18]-FDDNP</arm_group_label>
    <other_name>22-(1-{6-[(2-[F-18]fluoroethyl) (methyl)amino]-2-naphthyl} ethylidene) malononitrile</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject is male or female ≥ 40 years old;

          -  The individual has one of these three conditions:

          -  probable PSP according to criteria of the National Institute of Neurological Disorders
             and Stroke (NINDS)

          -  probable MSA according to criteria of the Second consensus statement on the diagnosis
             of multiple system atrophy

          -  unclassifiable parkinsonism according to criteria defined by Katzenschlager et al,
             2003:

          -  Patients with atypical parkinsonism without response to treatment with levodopa and
             does not meet any of the diagnostic criteria for other known atypical parkinsonism

          -  Patient given written consent

        Exclusion Criteria:

          -  The subject is diagnosed with Parkinson's Disease and meets the diagnostic criteria
             United Kingdom Parkinson's Disease Society Brain Bank -The subject is pregnant or
             breastfeeding;

          -  The subject has a history of drug abuse or alcohol;

          -  The subject has a moderate or severe renal function impairment (creatinine serum&gt; 1.5
             mg / dL);

          -  The subject has a moderate or severe hepatic impairment (bilirubin&gt; 2 times the upper
             limit of normal, transaminases&gt; 3 times the limit top of normal);

          -  The subject presents structural abnormalities in the basal ganglia or cortical level
             on MRI or CT;

          -  The subject has participated in a clinical study with a pharmaceutical product
             investigation within 30 days prior to screening and / or a radiopharmaceutical minimum
             period of 5 radioactive half-lives prior to screening;

          -  Occupational exposure to radiation&gt; 15 milliSievert (mSv) / year

          -  Use of nonsteroidal antiinflammatory drug (NSAIDs), for some reason, can not be
             replaced by any other drug 4 weeks before the PET scan;

          -  The subject has allergy investigational product or any of its components;

          -  The subject has a clinically severe active disease, with a hope reduced life;

          -  The subject is claustrophobic / a.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Jose Martí, Md, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació per a la Recerca Biomedica</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Katzenschlager R, Cardozo A, Avila Cobo MR, Tolosa E, Lees AJ. Unclassifiable parkinsonism in two European tertiary referral centres for movement disorders. Mov Disord. 2003 Oct;18(10):1123-31.</citation>
    <PMID>14534915</PMID>
  </reference>
  <reference>
    <citation>Litvan I, Bhatia KP, Burn DJ, Goetz CG, Lang AE, McKeith I, Quinn N, Sethi KD, Shults C, Wenning GK; Movement Disorders Society Scientific Issues Committee. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord. 2003 May;18(5):467-86.</citation>
    <PMID>12722160</PMID>
  </reference>
  <reference>
    <citation>Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, Wood NW, Colosimo C, Dürr A, Fowler CJ, Kaufmann H, Klockgether T, Lees A, Poewe W, Quinn N, Revesz T, Robertson D, Sandroni P, Seppi K, Vidailhet M. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008 Aug 26;71(9):670-6. doi: 10.1212/01.wnl.0000324625.00404.15.</citation>
    <PMID>18725592</PMID>
  </reference>
  <reference>
    <citation>Golbe LI, Ohman-Strickland PA. A clinical rating scale for progressive supranuclear palsy. Brain. 2007 Jun;130(Pt 6):1552-65. Epub 2007 Apr 2.</citation>
    <PMID>17405767</PMID>
  </reference>
  <reference>
    <citation>Wenning GK, Tison F, Seppi K, Sampaio C, Diem A, Yekhlef F, Ghorayeb I, Ory F, Galitzky M, Scaravilli T, Bozi M, Colosimo C, Gilman S, Shults CW, Quinn NP, Rascol O, Poewe W; Multiple System Atrophy Study Group. Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov Disord. 2004 Dec;19(12):1391-402.</citation>
    <PMID>15452868</PMID>
  </reference>
  <reference>
    <citation>Wong KP, Wardak M, Shao W, Dahlbom M, Kepe V, Liu J, Satyamurthy N, Small GW, Barrio JR, Huang SC. Quantitative analysis of [18F]FDDNP PET using subcortical white matter as reference region. Eur J Nucl Med Mol Imaging. 2010 Mar;37(3):575-88. doi: 10.1007/s00259-009-1293-8. Epub 2009 Oct 31.</citation>
    <PMID>19882153</PMID>
  </reference>
  <reference>
    <citation>Buongiorno M, Compta Y, Martí MJ. Amyloid-β and τ biomarkers in Parkinson's disease-dementia. J Neurol Sci. 2011 Nov 15;310(1-2):25-30. doi: 10.1016/j.jns.2011.06.046. Epub 2011 Jul 20. Review.</citation>
    <PMID>21764078</PMID>
  </reference>
  <reference>
    <citation>Smid LM, Vovko TD, Popovic M, Petric A, Kepe V, Barrio JR, Vidmar G, Bresjanac M. The 2,6-disubstituted naphthalene derivative FDDNP labeling reliably predicts Congo red birefringence of protein deposits in brain sections of selected human neurodegenerative diseases. Brain Pathol. 2006 Apr;16(2):124-30.</citation>
    <PMID>16768752</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2014</study_first_submitted>
  <study_first_submitted_qc>August 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2014</study_first_posted>
  <last_update_submitted>February 3, 2016</last_update_submitted>
  <last_update_submitted_qc>February 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundacion Clinic per a la Recerca Biomédica</investigator_affiliation>
    <investigator_full_name>Maria Jose Martí</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Unclassifiable Parkinsonism, [F18]-FDDNP-PET, Tauopathy, PSP,MSA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Supranuclear Palsy, Progressive</mesh_term>
    <mesh_term>Parkinsonian Disorders</mesh_term>
    <mesh_term>Tauopathies</mesh_term>
    <mesh_term>Multiple System Atrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Radiopharmaceuticals</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

